Michael Carter, MD
Family Medicine · Erin, TNNPI 1639293871
Payments from drug & device makers
Across 248 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$451
- AstraZeneca$243
- Sunovion Pharmaceuticals Inc.$232
- Lilly USA, LLC$218
- Boehringer Ingelheim$213
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,159100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $1,178 |
| AbbVie(2 entities) | 30 | $451 |
| AstraZeneca | 14 | $243 |
| Sunovion Pharmaceuticals Inc. | 16 | $232 |
| Lilly USA, LLC | 14 | $218 |
| Boehringer Ingelheim | 12 | $213 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $172 |
| Bayer | 6 | $142 |
| Teva Pharmaceuticals USA, Inc. | 6 | $117 |
| Nestle Healthcare Nutrition Inc. | 6 | $105 |
| Mylan Specialty L.p. | 7 | $104 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Johnson & Johnson | 5 | $92 |
| Merck | 5 | $89 |
| Medtronic(2 entities) | 5 | $77 |
| Lundbeck LLC | 4 | $76 |
| Pfizer | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Exact Sciences | 4 | $63 |
| Sun Pharmaceutical Industries Inc. | 3 | $62 |
| Amgen | 3 | $52 |
| Viatris Specialty LLC | 2 | $35 |
| Verona Pharma, Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Neurelis, Inc. | 2 | $21 |
| CMP Pharma, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$4,159 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 452 | $238,924 |
| JanuviaSitagliptin Phosphate | 145 | $105,928 |
| AustedoDeutetrabenazine | 17 | $99,242 |
| OzempicSemaglutide | 86 | $98,082 |
| LinzessLinaclotide | 144 | $93,182 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $85,409 |
| TrulicityDulaglutide | 47 | $57,619 |
| XareltoRivaroxaban | 100 | $53,964 |
| FarxigaDapagliflozin Propanediol | 73 | $50,273 |
| JardianceEmpagliflozin | 37 | $33,866 |
| MyrbetriqMirabegron | 71 | $29,349 |
| XifaxanRifaximin | 12 | $22,255 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $22,029 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,137 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $19,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $238,924452 claims |
| MerckJanuvia, Janumet Xr | $89 | $124,944159 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $15 | $106,546145 claims |
| AbbVieLinzess, Namzaric | $451 | $101,588174 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $117 | $99,24217 claims |
| Novo NordiskOzempic | $1,178 | $98,08286 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat, Stiolto Respimat | $213 | $83,417124 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $218 | $74,76663 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $243 | $72,301108 claims |
| Johnson & JohnsonXarelto | $92 | $53,964100 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $172 | $22,25512 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $97 | $16,16314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Erin
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.